1-[(2,4-difluorophenyl)methyl]-5-ethyl-7,7-dimethyl-8H-imidazo[2,1-b]purin-4-one | 1094568-28-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-[(2,4-difluorophenyl)methyl]-5-ethyl-7,7-dimethyl-8H-imidazo[2,1-b]purin-4-one
• CAS: 1094568-28-1
• 化学式: C₁₈H₁₉F₂N₅O
• 分子量: 359.379
• InChiKey: LMPWQFVMTMUHLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  53.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[(2,4-difluorophenyl)methyl]-5-ethyl-7,7-dimethyl-8H-imidazo[2,1-b]purin-4-one 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-bromo-1-[(2,4-difluorophenyl)methyl]-5-ethyl-7,7-dimethyl-8H-imidazo[2,1-b]purin-4-one
  参考文献：
  名称：

  Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 2

  摘要：

  Novel P2X(7) antagonists were developed using a purine scaffold. These compounds were potent and selective at the P2X(7) receptor in human and rodent as well as efficacious in rodent pain models. Compound 15a was identified to have oral potency in several pain models in rodent similar to naproxen, gabapentin and pregabalin. Structure-activity relationship (SAR) development and results of pain models are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.037
• 作为产物：
  描述：

  2,4-二氟氯苄 在 氯化亚砜 、 水 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 97.0h， 生成 1-[(2,4-difluorophenyl)methyl]-5-ethyl-7,7-dimethyl-8H-imidazo[2,1-b]purin-4-one
  参考文献：
  名称：

  Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 2

  摘要：

  Novel P2X(7) antagonists were developed using a purine scaffold. These compounds were potent and selective at the P2X(7) receptor in human and rodent as well as efficacious in rodent pain models. Compound 15a was identified to have oral potency in several pain models in rodent similar to naproxen, gabapentin and pregabalin. Structure-activity relationship (SAR) development and results of pain models are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.037

文献信息

• [EN] DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE 7,8-DIHYDRO-1H-IMIDAZO[2,1-B]PURIN-4(5H)-ONE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：SCHERING CORP

  公开号：WO2011079000A1

  公开（公告）日：2011-06-30

  The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease.

  本发明涉及7,8-二氢-1H-咪唑[2,1-b]嘌呤-4(5H)-酮的衍生物，以及其组合物和治疗或预防疼痛或炎症性疾病的使用方法。
• POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF
  申请人：Tulshian Deen

  公开号：US20110065738A1

  公开（公告）日：2011-03-17

  The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.

  本发明涉及多环鸟嘌呤衍生物，包括多环鸟嘌呤衍生物的组合物和使用多环鸟嘌呤衍生物治疗疼痛或炎症性疾病的方法。
• DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
  申请人：Tulshian Deen

  公开号：US20120316176A1

  公开（公告）日：2012-12-13

  The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease.

  本发明涉及7,8-二氢-1H-咪唑[2,1-b]嘌呤-4(5H)-酮的衍生物，以及其组合物和使用方法，用于治疗或预防疼痛或炎症性疾病。
• US8349858B2
  申请人：——

  公开号：US8349858B2

  公开（公告）日：2013-01-08
• [EN] POLYCYCLIC GUANINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE GUANINE POLYCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2009002423A2

  公开（公告）日：2008-12-31

  [EN] The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.
  [FR] La présente invention porte sur des Dérivés de Guanine Polycycliques, sur des compositions comprenant les Dérivés de Guanine Polycycliques et sur des procédés d'utilisation des Dérivés de Guanine Polycycliques pour traiter la douleur ou une maladie inflammatoire.